Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCV-116CCB in Chinese subjects with hypertension not controlled by amlodipine
NCT02969265Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- May 2017
- Primary completion
- Jul 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil in essential hypertension (2 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure (SBP) at Week 8. Planned start May 2017; status: withdrawn.
02
Drugs
candesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02969265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969265.